Brain enzyme is double whammy for Alzheimer's disease

August 20, 2012, Sanford-Burnham Medical Research Institute
This shows beta-amyloid plaques (red) in the brain of an Alzheimer's disease patient. Credit: Sanford-Burnham Medical Research Institute

The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed by the activity of several enzymes, including one called BACE1. Most Alzheimer's disease patients have elevated levels of BACE1, which in turn leads to more brain-damaging β-amyloid protein.

In a paper published August 15 in The Journal of Neuroscience, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) found that BACE1 does more than just help produce β-amyloid—it also regulates another cellular process that contributes to memory loss. This means that just inhibiting BACE1's enzymatic activity as a means to prevent or treat Alzheimer's disease isn't enough—researchers will have to prevent cells from making it at all.

"Memory loss is a big problem—not just in Alzheimer's disease, but also in the normal aging population," said Huaxi Xu, Ph.D., professor in Sanford-Burnham's Del E. Webb Neuroscience, Aging, and Stem Cell Research Center and senior author of the study. "In this study, we wanted to better understand how BACE1 plays a role in memory loss, apart from β-amyloid production."

To do this, Xu and his team used a mouse model that produces human BACE1. Mice produce a different type of β-amyloid, one that's far less toxic than the human version. So, in this system, they could look solely at how BACE1 functions independent from β-amyloid formation. If BACE1 only acted to produce β-amyloid, the researchers would expect to see no effect when mice produce human BACE1—since mouse β-amyloid isn't very toxic, extra BACE1 would be no big deal. Instead, they saw that the enzyme still impaired learning and memory, indicating a secondary function at work.

If it's not producing β-amyloid, what is BACE1 doing? Many years ago, scientists found that a protein in the brain—protein kinase A (PKA), better known for directing cellular metabolism—also plays an important role in memory formation. In this study, Xu and colleagues found that BACE1 disrupts the cell's production of other molecules required for PKA function. By that mechanism, BACE1 inactivates PKA and therefore inhibits memory formation in mice, even in the absence of neurotoxic β-amyloid.

"So BACE1 is a double whammy when it comes to memory," Xu said. "But that also means that a therapy that targets BACE1 could be a double punch against , and even just normal aging-related . That's why we're now looking for ways to block BACE1 expression in the brain."

Explore further: New drug target improves memory in mouse model of Alzheimer's disease

Related Stories

New drug target improves memory in mouse model of Alzheimer's disease

March 7, 2012
(Medical Xpress) -- Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the ...

Potential new drug candidate found for Alzheimer's disease

May 31, 2011
Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, ...

Poor recycling of BACE1 enzyme could promote Alzheimer's disease

November 21, 2011
Sluggish recycling of a protein-slicing enzyme could promote Alzheimer's disease, according to a study published online on November 21 in The Journal of Cell Biology.

Diametric shift in 2 protein levels spurs Alzheimer's plaque accumulation

December 1, 2011
A diametric shift in the levels of two proteins involved in folding, moving and cutting other proteins enables accumulation of the destructive brain plaque found in Alzheimer's disease, researchers report.

Recommended for you

A new way of thinking about tau kinetics, an essential component of Alzheimer's disease

March 21, 2018
Alzheimer's disease is most often characterized by two different pathologies in the brain: plaque deposits of a protein called beta-amyloid and tangles of another protein called tau. A paper appearing March 21 in the journal ...

Could drugs used after an organ transplant protect against Alzheimer's?

March 21, 2018
A UT Southwestern study in mice provides new clues about how a class of anti-rejection drugs used after organ transplants may also slow the progression of early-stage Alzheimer's disease.

Cell therapy could improve brain function for Alzheimer's disease

March 15, 2018
Like a great orchestra, your brain relies on the perfect coordination of many elements to function properly. And if one of those elements is out of sync, it affects the entire ensemble. In Alzheimer's disease, for instance, ...

Physically fit women nearly 90 percent less likely to develop dementia

March 14, 2018
Women with high physical fitness at middle age were nearly 90 percent less likely to develop dementia decades later, compared to women who were moderately fit, according to a study published the March 14, 2018, online issue ...

Poor sleep may heighten Alzheimer's risk

March 12, 2018
(HealthDay)—Older adults who are sleepy during the day might have harmful plaque building in their brain that is a sign of impending Alzheimer's disease, researchers report.

Dementia patients with distorted memories may actually retain key information – researchers say

March 7, 2018
Some memories containing inaccurate information can be beneficial to dementia sufferers because it enables them to retain key information researchers say.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.